Adam Chamberlin

3.1k total citations · 1 hit paper
31 papers, 2.3k citations indexed

About

Adam Chamberlin is a scholar working on Molecular Biology, Genetics and Organic Chemistry. According to data from OpenAlex, Adam Chamberlin has authored 31 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 9 papers in Genetics and 6 papers in Organic Chemistry. Recurrent topics in Adam Chamberlin's work include Genomics and Rare Diseases (6 papers), Ion channel regulation and function (6 papers) and Spectroscopy and Quantum Chemical Studies (4 papers). Adam Chamberlin is often cited by papers focused on Genomics and Rare Diseases (6 papers), Ion channel regulation and function (6 papers) and Spectroscopy and Quantum Chemical Studies (4 papers). Adam Chamberlin collaborates with scholars based in United States, Canada and Spain. Adam Chamberlin's co-authors include Christopher J. Cramer, Donald G. Truhlar, Rosendo Valero, Manjeera Mantina, Sergei Y. Noskov, H. Peter Larsson, Feng Qiu, Yibo Wang, Steven M. Bachrach and Tatiana K. Rostovtseva and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Molecular Biology.

In The Last Decade

Adam Chamberlin

30 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Consistent van der Waals Radii for the Whole Main Group

2009 1.5k citations Adam Chamberlin, Christopher J. Cramer et al. profile →

Peers

Countries citing papers authored by Adam Chamberlin

Since Specialization

Citations

This map shows the geographic impact of Adam Chamberlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Chamberlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Chamberlin more than expected).

Fields of papers citing papers by Adam Chamberlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam Chamberlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Chamberlin. The network helps show where Adam Chamberlin may publish in the future.

Co-authorship network of co-authors of Adam Chamberlin

This figure shows the co-authorship network connecting the top 25 collaborators of Adam Chamberlin. A scholar is included among the top collaborators of Adam Chamberlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Chamberlin. Adam Chamberlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Integration of protein stability and AlphaMissense scores improves bioinformatic impact prediction for p53 missense and in-frame amino acid deletion variants 2025 ·The American Journal of Human Genetics ·(unknown), Cristina Fortuño, (unknown), Adam Chamberlin, (unknown), Bing Feng, Miguel de la Hoya, Marcy E. Richardson, Amanda B. Spurdle	1
2	ACMG/AMP interpretation of BRCA1 missense variants: Structure-informed scores add evidence strength granularity to the PP3/BP4 computational evidence 2025 ·The American Journal of Human Genetics ·(unknown), (unknown), (unknown), Cristina Fortuño, (unknown), (unknown), Adam Chamberlin, Marcy E. Richardson, Kyriaki Michailidou, Pedro Pérez‐Segura, Amanda B. Spurdle, Miguel de la Hoya	1
3	Structural biology in variant interpretation: Perspectives and practices from two studies 2025 ·The American Journal of Human Genetics ·(unknown), Marcy E. Richardson, Adam Chamberlin	0
4	Saturation-scale functional evidence supports clinical variant interpretation in Lynch syndrome 2022 ·Genome biology ·Anthony Scott, Felicia Hernandez, Adam Chamberlin, (unknown), Rachid Karam, Jacob O. Kitzman	18
5	Three Newly Recognized Likely Pathogenic Gene Variants Associated with Hereditary Transthyretin Amyloidosis 2022 ·Neurology and Therapy ·J. Patel, Andrew M. Rosen, Adam Chamberlin, (unknown), (unknown), Heather Zimmermann, (unknown), Arvind Narayana	7
6	REVEL and BayesDel outperform other in silico meta-predictors for clinical variant classification 2019 ·Scientific Reports ·Yuan Tian, Tina Pesaran, Adam Chamberlin, R. Bryn Fenwick, Shuwei Li, Chia‐Ling Gau, Elizabeth Chao, Hsiao‐Mei Lu, Mary Helen Black, Dajun Qian	58
7	Biallelic mutations in FDXR cause neurodegeneration associated with inflammation 2018 ·Journal of Human Genetics ·Jesse Slone, Yanyan Peng, Adam Chamberlin, Belinda S. Harris, Julie Kaylor, (unknown), Monica E. Lemmon, (unknown), Dmitry Tchapyjnikov, (unknown), Elizabeth A. Sellars, Allyn McConkie‐Rosell, Laura G. Reinholdt, Taosheng Huang	26
8	DNA breakpoint assay reveals a majority of gross duplications occur in tandem reducing VUS classifications in breast cancer predisposition genes 2018 ·Genetics in Medicine ·Marcy E. Richardson, Hansook Kim Chong, Wenbo Mu, (unknown), Vickie Hsuan, (unknown), Stéphanie Lam, (unknown), Tina Pesaran, Adam Chamberlin, Minsun Park, Phillip Gray, Rachid Karam, Aaron Elliott	15
9	Whole-exome sequencing uncovers oxidoreductases DHTKD1 and OGDHL as linkers between mitochondrial dysfunction and eosinophilic esophagitis 2018 ·JCI Insight ·Joseph D. Sherrill, Kiran KC, Xinjian Wang, Ting Wen, Adam Chamberlin, Emily M. Stucke, Margaret H. Collins, J. Pablo Abonia, Yanyan Peng, Qiang Wu, Philip E. Putnam, Phillip J. Dexheimer, Bruce J. Aronow, Leah C. Kottyan, Kenneth M. Kaufman, John B. Harley, Taosheng Huang, Marc E. Rothenberg	41
10	De Novo Variants in GRIA4 Lead to Intellectual Disability with or without Seizures and Gait Abnormalities 2017 ·The American Journal of Human Genetics ·(unknown), Adam Chamberlin, Deepali N. Shinde, Maja Hempel, Tim M. Strom, Allison Schreiber, Jessika Johannsen, Lilian Bomme Ousager, Martin J. Larsen, Lars Kjærsgaard Hansen, Ali Fatemi, Julie S. Cohen, Johannes R. Lemke, Kristina P. Sørensen, Katherine L. Helbig, Davor Lessel, Rami Abou Jamra	43
11	Postmortem Diagnostic Exome Sequencing Identifies a De Novo TUBB3 Alteration in a Newborn With Prenatally Diagnosed Hydrocephalus and Suspected Walker–Warburg Syndrome 2017 ·Pediatric and Developmental Pathology ·Zöe Powis, Adam Chamberlin, (unknown), (unknown), Lynne M. Bird, Sha Tang	6
12	Current state of theoretical and experimental studies of the voltage-dependent anion channel (VDAC) 2016 ·Biochimica et Biophysica Acta (BBA) - Biomembranes ·Sergei Y. Noskov, Tatiana K. Rostovtseva, Adam Chamberlin, Oscar Teijido, Wei Jiang, Sergey M. Bezrukov	51
13	Beyond DNA: An Integrated and Functional Approach for Classifying Germline Variants in Breast Cancer Genes 2016 ·International Journal of Breast Cancer ·Tina Pesaran, Rachid Karam, Robert Huether, (unknown), Suzette Farber-Katz, Adam Chamberlin, Hansook Kim Chong, Holly LaDuca, Aaron Elliott	54
14	Mapping the Gating and Permeation Pathways in the Voltage-Gated Proton Channel Hv1 2014 ·Journal of Molecular Biology ·Adam Chamberlin, Feng Qiu, Yibo Wang, Sergei Y. Noskov, H. Peter Larsson	28
15	Acidification Asymmetrically Affects Voltage-dependent Anion Channel Implicating the Involvement of Salt Bridges 2014 ·Journal of Biological Chemistry ·Oscar Teijido, (unknown), Adam Chamberlin, Sergei Y. Noskov, Vicente M. Aguilella, Tatiana K. Rostovtseva, Sergey M. Bezrukov	39
16	Rehabilitating drug-induced long-QT promoters: In-silico design of hERG-neutral cisapride analogues with retained pharmacological activity 2014 ·BMC Pharmacology and Toxicology ·Serdar Durdağı, Trevor E. Randall, Henry J. Duff, Adam Chamberlin, Sergei Y. Noskov	16
17	Hydrophobic plug functions as a gate in voltage-gated proton channels 2013 ·Proceedings of the National Academy of Sciences ·Adam Chamberlin, Feng Qiu, Santiago Rebolledo, Yibo Wang, Sergei Y. Noskov, H. Peter Larsson	69
18	Iron Porphyrin Dications with Neutral Axial Ligands: DFT Calculations Delineate Similarities with Heme Protein Compound II Intermediates 2011 ·The Journal of Physical Chemistry B ·Adam Chamberlin, Akira Ikezaki, Mikio Nakamura, Abhik Ghosh	7
19	Performance of SM8 on a Test To Predict Small-Molecule Solvation Free Energies 2008 ·The Journal of Physical Chemistry B ·Adam Chamberlin, Christopher J. Cramer, Donald G. Truhlar	58
20	Extension of a Temperature-Dependent Aqueous Solvation Model to Compounds Containing Nitrogen, Fluorine, Chlorine, Bromine, and Sulfur 2008 ·The Journal of Physical Chemistry B ·Adam Chamberlin, Christopher J. Cramer, Donald G. Truhlar	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact